Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials)

Affiliations

• ¹ Neuro Immuno-Inflammation Therapeutic Area, Institut de Recherches Internationales Servier, Suresnes, France.
• ² Child & Adolescent Psychiatry Service, Policlínica Gipuzkoa & GAUTENA Autism Society, San Sebastián, Spain.
• ³ Department of Neonatal Pediatrics, CHU de Rouen and CHU Le Rouvray, Sotteville les Rouen, France.
• ⁴ Child and Adolescent Mental Health Service, Hospital Universitari Mútua de Terrassa, and Global Institute of Neurodevelopment Integrated Care (IGAIN), Barcelona, Spain.
• ⁵ Department of Neonatal Pediatrics, Intensive Care, and Neuropediatrics, Rouen University Hospital, Rouen, France.
• ⁶ INSERM U 1245 team 4 Neovasc, School of Medicine, Normandy University, Rouen, France.
• ⁷ Neurodevelopmental and Autism Unit from Child Developmental Center and Centro de Investigação e Formação Clínica, Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
• ⁸ Faculty of Medicine, University Clinic of Pediatrics, University of Coimbra, Coimbra, Portugal.
• ⁹ Servicio de Psiquiatría del Niño y del Adolescente Hospital General Universitario Gregorio Marañón, CIBERSAM, IiSGM, Ibiza 43, Madrid, Spain.
• ¹⁰ Global Medical and Patient Affairs, Servier, 35 rue de Verdun, 92284, Suresnes cedex, Suresnes, France. simon.kyaga@servier.com.
• ¹¹ Neurochlore, Marseille, France.
• ¹² University Paris-Sud, Univ. Paris-Descartes, AP-HP, INSERM U1178, Paris, France.